According to Pokhare and colleagues (2022[35]), the identification of biomarkers, such as GAL3, using easily available immunohistochemical assays could improve risk stratification in lung cancer patients (Pokhare et al., 2022[35]), highlighting the importance of considering this biomarker even more in future studies. This evidence concerns the gene LGALS3 and lung carcinoma.